Astec Lifesciences Ltd

AI
Astec Lifescienc Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Astec Lifesciences Ltd

₹ 556 1.35%
03 Nov - close price
godrejastec.com BSE: 533138 NSE: ASTEC
About

The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.
Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).[1] [2] [3]

Key Points

Product Portfolio:[1]
The company offers a range of products
and intermediates such as Tebuconazole, Propiconazole, Hexaconazole, Difenoconazole, Metconazole, Cyproconazole, Prothioconazole, Metalaxyl/Metalaxyl-M and Flutriafol; Quizalofop, Imazethapyr and sulfonylurea herbicides; plant-growth regulator Paclobutrazol; household insecticide Transfluthrin; and intermediates. These control fungal disease, weeds and insects.
CDMO covers process development,
analytical and safety studies, pilot scale
-up, qualification samples, plant design
and commercial manufacture of starting materials, active ingredients and advanced intermediates for crop science, life science
and consumer-product customers.[2]

Website BSE NSE
  • Market Cap ₹ 1,237 Cr.
  • Current Price ₹ 556
  • High / Low ₹ 942 / 512
  • Stock P/E
  • Book Value ₹ 150
  • Dividend Yield 0.00 %
  • ROCE -5.46 %
  • ROE -25.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Stock is trading at 3.71 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -4.18% over past five years.
  • Company has a low return on equity of -26.1% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 202 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals

Part of BSE Commodities

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
111 51 154 69 99 94 120 91 74 125 159 84 72
114 69 141 116 118 100 114 102 80 121 149 84 92
Operating Profit -3 -18 13 -46 -20 -6 6 -11 -7 4 9 -1 -20
OPM % -3.1% -36% 8% -67% -20% -6% 4.6% -12% -9% 3.2% 6% -0.8% -27%
1 1 2 1 2 2 1 0 1 -1 3 1 1
Interest 6 6 7 7 9 10 10 11 8 7 8 8 7
Depreciation 9 9 9 9 11 11 12 12 10 11 12 11 11
Profit before tax -18 -32 -1 -62 -39 -25 -16 -33 -24 -16 -8 -19 -37
Tax % -24% -24% 3% -36% 0% 60% 3% 0% 0% 0% -2% -0% -0%
-13 -24 -1 -40 -39 -40 -16 -33 -24 -16 -8 -19 -37
EPS in Rs -6.79 -12.30 -0.50 -20.07 -19.48 -20.40 -8.13 -16.70 -10.97 -7.06 -3.49 -8.41 -16.80
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
252 221 298 368 431 522 555 677 628 458 381 448 439
200 190 236 299 354 437 443 522 551 464 447 453 446
Operating Profit 52 31 63 69 76 85 112 154 77 -6 -66 -4 -7
OPM % 21% 14% 21% 19% 18% 16% 20% 23% 12% -1.3% -17% -1.0% -1.7%
-15 -0 -8 12 11 12 8 10 13 5 6 3 3
Interest 12 12 12 11 12 13 5 9 21 25 37 35 30
Depreciation 12 10 14 15 19 23 26 34 34 36 44 45 45
Profit before tax 12 8 29 56 56 61 89 121 35 -62 -141 -81 -80
Tax % -18% 95% 33% 37% 36% 23% 27% 26% 27% -24% -4% -0%
15 0 19 35 36 47 65 90 26 -47 -135 -81 -80
EPS in Rs 7.54 0.18 9.69 17.75 18.12 24.10 32.84 45.59 12.89 -23.73 -68.09 -36.36 -35.76
Dividend Payout % 16% 0% 15% 8% 8% 6% 5% 3% 12% 0% 0% 0%
Compounded Sales Growth
10 Years: 7%
5 Years: -4%
3 Years: -11%
TTM: 16%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 32%
Stock Price CAGR
10 Years: -1%
5 Years: -16%
3 Years: -24%
1 Year: -17%
Return on Equity
10 Years: 2%
5 Years: -8%
3 Years: -26%
Last Year: -25%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 19 19 20 20 20 20 20 20 20 20 20 22 22
Reserves 117 99 118 150 183 227 289 376 399 349 214 368 312
93 127 127 125 176 99 188 280 341 494 555 449 331
128 84 69 119 83 227 182 221 219 111 92 102 129
Total Liabilities 358 329 334 413 461 572 678 897 979 974 880 941 794
127 94 103 115 167 194 213 340 318 386 499 459 457
CWIP 12 20 8 42 19 24 116 23 127 165 21 20 1
Investments 1 0 0 0 0 0 0 0 0 0 0 0 0
217 214 223 256 275 354 349 534 533 423 360 462 335
Total Assets 358 329 334 413 461 572 678 897 979 974 880 941 794

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
3 3 19 65 15 169 -8 23 74 10 -8 -81
-14 -16 -18 -49 -52 -74 -73 -104 -112 -135 -15 -4
11 15 -1 -18 37 -95 81 80 38 125 24 94
Net Cash Flow -0 2 1 -2 -0 0 0 0 -0 0 0 9
Free Cash Flow -13 -23 -1 15 -37 123 -111 -80 -42 -125 -24 -85
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 11% 27% 41% 116% 42% 219% 13% 34% 103% -208% 20% 1,802%

Ratios

Standalone / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 143 132 136 122 103 112 123 148 90 135 141 202
Inventory Days 143 186 133 122 121 131 113 176 268 224 196 169
Days Payable 181 179 117 156 83 219 137 180 161 102 100 107
Cash Conversion Cycle 105 140 152 88 141 24 99 145 197 256 237 263
Working Capital Days 17 -29 0 -8 -2 8 4 12 -17 -1 -26 -56
ROCE % 20% 10% 20% 22% 20% 20% 22% 22% 8% -4% -13% -5%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
R&D expenditure as percentage of total turnover
% of turnover

Log in to view insights

Please log in to see hidden values.

Login
Export share of total revenue
% of revenue
Total permanent employees
employees
CDMO/Contract Manufacturing share of total revenue
% of revenue
Number of countries exported to
countries
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

10 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
66.75% 66.75% 66.75% 66.74% 66.74% 70.87% 70.87% 72.42% 71.97% 71.97% 71.97% 71.97%
1.28% 1.25% 1.03% 0.53% 1.20% 0.25% 0.02% 0.00% 0.04% 0.03% 0.01% 0.02%
9.74% 7.88% 3.37% 4.50% 5.40% 4.34% 4.26% 4.01% 3.17% 3.33% 3.33% 3.34%
22.22% 24.12% 28.85% 28.20% 26.64% 24.53% 24.84% 23.57% 24.82% 24.67% 24.69% 24.67%
No. of Shareholders 19,24419,84819,95519,72719,05718,68918,54918,27622,29321,04119,88919,707

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls